Regenerative Patch Technologies LLC (RPT) is a California company developing cell-based implant technology for the treatment of retinal diseases. CPCB-RPE1 is RPT’s lead product.
RPT was founded by Drs. Mark Humayun and David R. Hinton from the University of Southern California and Dr. Dennis O. Clegg from UC Santa Barbara. The technology to produce the CPCB-RPE1 implant is exclusively licensed to RPT from the University of Southern California, the California Institute of Technology and UC at Santa Barbara.
For additional information contact:
(833)-REGENPT (833) 734-3678
The implant is exclusively for use within the current clinical trial and not available for other experimental indications or compassionate use at this time.